Sight Sciences today marks a significant milestone for the OMNI® Surgical System in the United Kingdom, with more than 10,000 procedures performed across NHS and private hospitals since its UK launch in 2020.
The milestone reflects the growing integration of OMNI into routine glaucoma care, where it is used by UK surgeons in both combined cataract surgery and standalone procedures for patients with open-angle glaucoma (OAG).
OMNI is among the most regularly-performed minimally-invasive glaucoma surgery (MIGS) procedures in the UK. Its continued adoption reflects surgeon confidence in the technology designed to address resistance across the conventional aqueous outflow pathway, supporting restoration of physiological outflow and reduction of intraocular pressure.
Sight Sciences is dedicated to transforming eyecare through minimally invasive, targeted interventions that address the root causes of disease. Since launching OMNI in the UK in 2020, the company has seen a strong uptake across both NHS and private practice settings with clinicians using OMNI for a wide range of patient profiles and disease severities.
To date, more than 150 UK surgeons have completed certification to perform OMNI procedures, with adoption spanning over 50 NHS trusts nationwide. This breadth of use highlights the transition of OMNI from early adoption to an established part of interventional glaucoma practice in the UK.
L: Andrew Tatham R; Steve Mitchley.
Commenting on the milestone, Andrew Tatham, Consultant Ophthalmologist, said:
“Ten thousand patients treated with OMNI is an impressive landmark. It is heartening to see the continued and widespread adoption of OMNI across the UK, meaning that more glaucoma patients are benefitting from a procedure which surgeons trust for its versatility, efficacy and safety.”
The OMNI® Surgical System is the first and only MIGS device indicated for both canaloplasty and trabeculotomy, with a growing body of clinical evidence supporting its use and favourable safety profile.
Sight Sciences is dedicated to transforming eyecare through minimally invasive, targeted interventions that address the root causes of disease. The company is committed to supporting UK surgeons through a structured programme of certification, clinical support and peer-to-peer education, helping to underpin consistent surgical practice and high-quality patient care as OMNI adoption continues to expand.
FURTHER INFORMATION:
To learn more about OMNI or to request a demo please contact:
glaucomaUK@sightsciences.com
